Tralokinumab regarding moderate-to-severe atopic eczema: results from a pair of 52-week, randomized, double-blind, multicentre, placebo-controlled cycle III tests (ECZTRA One as well as ECZTRA Two).
https://www.selleckchem.com/pr....oducts/AG-014699.htm